Skip to main content

Table 2 Correlation between CHD5 expression and clinicopathological parameters in breast cancer

From: Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer

Parameters

CHD5 expression (n)

Total cases

P-values

 

-

+

  

Age (years)

  

289

0.590

   ≤ 50

67

62

129

 

   > 50

78

82

160

 

Tumor size

  

288*

0.476

   ≤ 2 cm

29

34

63

 

   > 2 cm

115

110

225

 

Histological grade

  

275*

0.010

   I

4

14

18

 

   II

100

103

203

 

   III

34

20

54

 

pTNM stage

  

284*

0.105

   I/II

99

111

210

 

   III/IV

43

31

74

 

LN metastasis

  

289

0.215

   -

57

67

124

 

   +

88

77

165

 

Estrogen receptor

  

289

0.009

   -

66

44

110

 

   +

79

100

179

 

Progesterone receptor

  

289

0.001

   -

84

54

138

 

   +

61

90

151

 

HER2 status

  

289

< 0.001

   -

74

111

185

 

   +

71

33

104

 

Molecular subtype

  

289

< 0.001

   luminal A

54

95

149

 

   luminal B

35

12

47

 

   HER2

37

20

57

 

   Triple negative

19

17

36

 

Family history

  

264*

0.420

   No

105

98

203

 

   Yes

28

33

61

 

Distant metastasis

  

289

< 0.001

   No

115

137

252

 

   Yes

30

7

37

 

Death

  

289

0.001

   No

125

140

265

 

   Yes

20

4

24

 
  1. Notes: LN, lymph node; pTNM, pathological tumor node metastasis; *, analysis was limited to patients whose relevant information was available. Molecular subtypes were defined as below: luminal A, ER+ and/or PR+/HER2-; luminal B, ER+ and/or PR+/HER2+; HER2+, ER-/PR-/HER2+; and triple negative, ER-/PR-/HER2-. CHD5 expression is categorized into two groups: lack of expression "-" and expression at various levels "+". P-values were determined by the Chi-square (χ2) test.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us